Categories: Healthcare

Clinical Biomarkers Market growth, size, and overview by 2024-2033

Overview and Scope

Clinical biomarkers refer to quantifiable biological traits identifying normal or diseased bodily functions, such as chemicals or physiological indices. Clinical biomarkers help enhance patient care and personalized medicine by offering valuable data about a person’s health condition, disease progression, and prospective therapeutic targets.

Sizing and Forecast

The clinical biomarkers market size has grown rapidly in recent years. It will grow from $27.66 billion in 2023 to $30.59 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased prevalence of chronic disease, focus on personalized medicine and targeted therapies, drug development and clinical trials, regulatory support and funding.

The clinical biomarkers market size is expected to see rapid growth in the next few years. It will grow to $46.11 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to expansion of companion diagnostics, focus on early diagnosis and disease prevention, increasing applications in precision oncology and neurodegenerative diseases, growing infectious diseases. Major trends in the forecast period include ai-powered biomarker discovery, machine learning integration, multi-omics integration, technological innovations, key players’ partnerships.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Segmentation & Regional Insights

The clinical biomarkers market covered in this report is segmented –

1) By Offering: Product, Service
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), Other Technologies
3) By Clinical Area: Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Immunological Biomarker, Non-Invasive Prenatal Testing, Other Clinical Areas
4) By Application: Clinical Diagnostic, Translational Research
5) By End User: Contract Research Organizations (CROs), Research and Academic Laboratories, Biopharmaceutical and Biotech Companies, Diagnostic Centers, Other End Users

North America was the largest region in the clinical biomakers market in 2023. The regions covered in the clinical biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12670&type=smp

Major Driver Impacting Market Growth

High cancer prevalence is expected to propel the growth of the clinical biomarker market going forward. Cancer is a term used to describe a group of disorders in which abnormal cells grow and divide uncontrollably, with the potential to invade and harm healthy bodily tissue. Clinical biomarkers play a crucial role in cancer prevention by aiding in early detection, risk assessment, and monitoring of individuals at high risk for developing cancer. For instance, in May 2021, according to the National Library of Medicine, a US-based medicine library, the global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Therefore, the high cancer prevalence is driving the growth of the clinical biomarker market.

Key Industry Players

Major companies operating in the clinical biomarkers market report are Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., Epigenomics AG, Grifols S.A., Illumina Inc., BioMerieux SA., Charles River Laboratories International Inc., PerkinElmer Inc., Sartorius AG, Sysmex Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Luminex Corporation, Veracyte Inc., Centogene N.V., NanoString Technologies Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Siemens Healthcare Private Limited.

The clinical biomarkers market report table of contents includes:

1. Executive Summary

2. Clinical Biomarkers Market Characteristics

3. Clinical Biomarkers Market Trends And Strategies

4. Clinical Biomarkers Market – Macro Economic Scenario

5. Global Clinical Biomarkers Market Size and Growth

…

32. Global Clinical Biomarkers Market Competitive Benchmarking

33. Global Clinical Biomarkers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Clinical Biomarkers Market

35. Clinical Biomarkers Market Future Outlook and Potential Analysis

36. Appendix